StemCells, Inc. : Groundbreaking Science. Breakthrough …

Posted: September 18, 2015 at 10:46 pm

StemCells, Inc. is engaged in clinical development of its proprietary HuCNS-SC (purified human neural stem cells) platform technology to treat disorders of the central nervous system (CNS). Learnmore

Spinal cord injury (SCI) is the second leading cause of paralysis in the U.S. Transplantation of HuCNS-SC cells holds much promise. Learnmore

StemCells, Inc. has been very professional. They have given me all the support that I need.

Phase I/II SCI Clinical Trial Patient Learnmore

StemCells, Inc. being controlled by a U.S. company, and the way they were following up with their patients, just made me feel safer.

Phase I/II SCI Clinical Trial Patient Learnmore

Age-related Macular Degeneration (AMD) is the leading cause of vision loss in developed countries. HuCNS-SC cells may be a viable therapy. Learnmore

I was not ready to give in and say I was going to be blind I was ready to be a pioneer.

Phase I/II AMD Clinical Trial Patient Learnmore

As a patient with a cervical SCI, you may be eligible to participate in a clinical research study called the Pathway Study. The study is evaluating human neural stem cell transplantation as a potential therapy for SCI.

Learn more about this clinical trial

2000 - StemCells, Inc. All Rights Reserved. Photography may be 2010 Lou Jones, StemCells, Inc. or others.

See the original post here:
StemCells, Inc. : Groundbreaking Science. Breakthrough ...

Related Posts